U.S. markets close in 4 hours 1 minute
  • S&P 500

    4,070.86
    -9.25 (-0.23%)
     
  • Dow 30

    34,295.62
    -294.15 (-0.85%)
     
  • Nasdaq

    11,462.43
    -5.56 (-0.05%)
     
  • Russell 2000

    1,886.87
    +0.30 (+0.02%)
     
  • Crude Oil

    82.10
    +1.55 (+1.92%)
     
  • Gold

    1,816.40
    +56.50 (+3.21%)
     
  • Silver

    22.77
    +0.99 (+4.56%)
     
  • EUR/USD

    1.0500
    +0.0092 (+0.88%)
     
  • 10-Yr Bond

    3.5780
    -0.1250 (-3.38%)
     
  • GBP/USD

    1.2249
    +0.0187 (+1.55%)
     
  • USD/JPY

    135.5490
    -2.5310 (-1.83%)
     
  • BTC-USD

    16,983.77
    +121.96 (+0.72%)
     
  • CMC Crypto 200

    402.43
    -3.72 (-0.92%)
     
  • FTSE 100

    7,558.49
    -14.56 (-0.19%)
     
  • Nikkei 225

    28,226.08
    +257.09 (+0.92%)
     

Orchard Therapeutics Issues Updates On Gene Therapy Programs

  • Orchard Therapeutics plc (NASDAQ: ORTX) has provided updates on the progress of its lead gene therapy programs targeting metachromatic leukodystrophy (MLD), mucopolysaccharidosis type I Hurler syndrome (MPS-IH), and Wiskott-Aldrich syndrome (WAS).

  • After receiving feedback from the FDA, the company expects to file a marketing application for OTL-200 in pre-symptomatic, early-onset MLD in late 2022 or early 2023.

  • The submission of the marketing application in Europe for OTL-103 in WAS has been delayed to 2022 from 2021. The timeline on application submission to the FDA, previously expected in 2022, is not finalized yet.

  • For OTL-203, Orchard anticipates the initiation of a study in 2022 targeting MPS-IH with a revised trial protocol incorporating the guidance given by the FDA and the European Medicines Agency.

  • Price Action: ORTX shares are down 3.81% at $4.67 during the market session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.